52 results on '"Koschmieder, Steffen"'
Search Results
2. Additional file 1 of Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis
3. Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET
4. Clonal haematopoiesis of indeterminate potential and impaired kidney function - A Danish general population study with 11 years follow-up
5. Leitlinie - Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h��matologischer und onkologischer Erkrankungen
6. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen : ICD-10 D47.1
7. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
8. JAK2-V617F and interferon-�� induce megakaryocyte-biased stem cells characterized by decreased long-term functionality
9. Long-term follow-up of recovered MPN patients with COVID-19
10. Additional file 7: of Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
11. Additional file 1: of Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
12. Additional file 8: of Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
13. Additional file 10: of Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
14. Additional file 9: of Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
15. Additional file 3: of Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
16. Additional file 2: of Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
17. Additional file 5: of Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
18. Additional file 4: of Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
19. Additional file 6: of Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
20. Additional file 11: of Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
21. Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options
22. Leitlinie - ICD10: D45 : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
23. Leitlinie - ICD-10 D47.1 : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
24. Primäre Myelofibrose (PFM)
25. Translationale Tumor-Medizin : Vom Molekül zur individualisierten onkologischen Diagnose und Therapie
26. Essentielle (oder primäre) Thrombozythämie (ET)
27. Additional file 1: of A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
28. Leitlinie - ICD-10 D47.3 : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
29. Higher rates of molecular response to Peg-IFNa in JAK2V617F vs. CALR mutant MPN patients are due to JAK1-mediated STAT1 activation and autoregulation
30. Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature
31. Intramolecular hydrophobic interactions are critical mediators of STAT5 dimerization
32. γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm
33. Additional file 1: Figure S1. of Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
34. Additional file 2: Figure S2. of Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
35. Additional file 5: Figure S5. of Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
36. Additional file 4: Figure S4. of Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
37. Additional file 3: Figure S3. of Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
38. Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
39. Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia - a randomised SAL pilot study
40. RUNX1 regulates the CD34 gene in haematopoietic stem cells by mediating interactions with a distal regulatory element
41. Mouse models as tools to understand and study BCR-ABL1 diseases
42. γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm
43. A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression
44. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms
45. Drug Target Optimization in Chronic Myeloid Leukemia Using Innovative Computational Platform
46. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis
47. Thrombelastometrie und Thrombingenerierung für die Bestimmung des prokoagulatorischen Zustandes bei Myeloproliferativen Neoplasien
48. Die duale Hemmung der BCR-ABL1 Kinase und des Proteasoms als neuer Therapieansatz in der BCR-ABL positiven akuten lymphatischen Leukämie
49. Dissecting the role of hypoxia-inducible factor 1 (HIF-1) in JAK2V617F-positive myeloproliferative neoplasms (MPN)
50. Modelling of disease progression in myeloproliferative neoplasms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.